Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

G. Feagan, Brian; J. Sandborn, William; Gasink, Christopher; Jacobstein, Douglas; Lang, Yinghua; R. Friedman, Joshua; Blank, Marion; Johanns, Jewel; Gao, Long-Long; Ye, Miao; J. Adedokun, Omoniyi; E. Sands, Bruce; B. Hanauer, Stephen; Vermeire, Séverine; R. Targan, Stephan; Ghosh, Subrata; J. de Villiers, Willem; Colombel, Jean–Frédéric; Tulassay, Zsolt; Seidler, Ursula; Salzberg, Bruce; Desreumaux, Pierre; D. Lee, Scott; V. Loftus, Edward; A. Dieleman, Levinus; Katz, Seymour; Rutgeerts, Paul

doi:10.1056/nejmoa1602773

Public

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

Published in New England Journal of Medicine • Nov 16, 2016

Authors:

Brian G. Feagan

William J. Sandborn

Christopher Gasink

Abstract

Ustekinumab, a monoclonal antibody to the p40 subunit of interleukin-12 and interleukin-23, was evaluated as an intravenous induction therapy in two populations with moderately to severely active Crohn's disease. Ustekinumab was also evaluated as subcutaneous maintenance therapy.

Subject

Ustekinumab

Medicine

Crohn's disease

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!